Surfing the p53 network.

The human disease network. Proc Natl Acad Sci U S A (2007) 19.58

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58

Modes of p53 regulation. Cell (2009) 9.31

The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A (2005) 7.38

Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell (2008) 6.93

Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46

Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37

miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24

Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07

TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92

When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86

Acetylation is indispensable for p53 activation. Cell (2008) 5.70

p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57

Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51

Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell (2006) 5.40

microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38

Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96

Reverse engineering gene networks: integrating genetic perturbations with dynamical modeling. Proc Natl Acad Sci U S A (2003) 4.89

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell (2011) 4.74

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68

Oscillations and variability in the p53 system. Mol Syst Biol (2006) 4.59

Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J (2002) 4.54

PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46

Mutant p53: one name, many proteins. Genes Dev (2012) 4.33

"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17

tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15

Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev (2002) 4.12

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09

Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol (2004) 4.08

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07

Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev (2006) 4.06

Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06

p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell (2007) 4.01

Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res (2006) 4.00

Cell signaling in space and time: where proteins come together and when they're apart. Science (2009) 3.88

Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84

Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81

p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol (2011) 3.70

Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction. Proc Natl Acad Sci U S A (2004) 3.60

A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A (2008) 3.57

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47

Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A (2006) 3.35

p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33

Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol (2004) 3.31

p53 dynamics control cell fate. Science (2012) 3.30

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27

Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell (2007) 3.23

Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21

Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell (2007) 3.20

USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17

Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06

p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88

MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78

Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75

Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 2.72

Prediction of protein binding regions in disordered proteins. PLoS Comput Biol (2009) 2.69

PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell (2008) 2.68

Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res (2008) 2.67

Escherichia coli mazEF-mediated cell death is triggered by various stressful conditions. J Bacteriol (2004) 2.66

BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med (2003) 2.62

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61

Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J (2004) 2.59

The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57

The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56

Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol (2008) 2.56

Nucleolus, ribosomes, and cancer. Am J Pathol (2008) 2.53

Compensatory proliferation in Drosophila imaginal discs requires Dronc-dependent p53 activity. Curr Biol (2006) 2.51

P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49

DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med (2002) 2.48

Network hubs buffer environmental variation in Saccharomyces cerevisiae. PLoS Biol (2008) 2.47

Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med (2001) 2.47

A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47

Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol (2008) 2.45

Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44

Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell (2010) 2.40

p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol (2009) 2.35

Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35

p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34

HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev (2007) 2.32

mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol (2003) 2.32

A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32

Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature (2008) 2.32

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30

The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28

Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27

Mutational spectra of human cancer. Hum Genet (2009) 2.26

Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep (2009) 2.26

Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J (2005) 2.25

Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A (2013) 2.22

A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev (2005) 2.21

Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science (2015) 2.20

Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem (2002) 2.19

A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19

Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18

E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev (2001) 2.16

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01

The sequence of the human genome. Science (2001) 101.55

"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58

Serial analysis of gene expression. Science (1995) 60.15

A genetic model for colorectal tumorigenesis. Cell (1990) 44.37

WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72

Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A (1999) 35.16

p53 mutations in human cancers. Science (1991) 31.96

Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci U S A (1979) 27.20

Lessons from hereditary colorectal cancer. Cell (1996) 25.73

Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61

A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58

Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25

Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80

Genetic instabilities in human cancers. Nature (1998) 22.76

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87

Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91

Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53

Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00

Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15

Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88

Definition of a consensus binding site for p53. Nat Genet (1992) 12.76

Genetic instability in colorectal cancers. Nature (1997) 12.51

The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53

Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41

A model for p53-induced apoptosis. Nature (1997) 11.38

Characterization of the yeast transcriptome. Cell (1997) 11.33

Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20

The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19

Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18

Genes expressed in human tumor endothelium. Science (2000) 10.75

Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (1992) 10.12

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66

Gene expression profiles in normal and cancer cells. Science (1997) 9.65

APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48

Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28

Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27

Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23

A public database for gene expression in human cancers. Cancer Res (1999) 8.81

PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90

STRAND SEPARATION AND SPECIFIC RECOMBINATION IN DEOXYRIBONUCLEIC ACIDS: BIOLOGICAL STUDIES. Proc Natl Acad Sci U S A (1960) 7.50

14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20

Association of the APC tumor suppressor protein with catenins. Science (1993) 7.17

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12

Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73

p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 6.66

Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61

Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60

Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 6.58

Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun (1985) 6.57

Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44

Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet (2001) 6.36

Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30

Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15

Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest (1999) 6.13

Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (1996) 6.11

Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02

Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88

Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 5.87

Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res (1998) 5.80

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res (1990) 5.70

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68

p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev (1995) 5.63

p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49

14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature (1999) 5.44

Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31

Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26

p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20

Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med (1994) 5.12

PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12

Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07

Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04

Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98

Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87

Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86

Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86

Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet (1998) 4.67

Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63

Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res (2001) 4.50

DNA replication in SV40 infected cells. I. Analysis of replicating SV40 DNA. J Mol Biol (1970) 4.49

Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49

Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol (1994) 4.43

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32

Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res (1987) 4.25

Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res (1992) 4.21

Identification of an amplified, highly expressed gene in a human glioma. Science (1987) 4.21

Gain of function mutations in p53. Nat Genet (1993) 4.19

Genetic instability and darwinian selection in tumours. Trends Cell Biol (1999) 4.12

Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09

Whole genome PCR: application to the identification of sequences bound by gene regulatory proteins. Nucleic Acids Res (1989) 4.07

Molecular diagnosis of familial adenomatous polyposis. N Engl J Med (1993) 4.07

Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06